Coherus Catapults into Immuno-oncology Field with US$1.8 B Junshi Alliance

By Michelle Liu

Pharma Deals Review: Vol 2021 Issue 2 (Table of Contents)

Published: 8 Feb-2021

DOI: 10.3833/pdr.v2021.i2.2592     ISSN: 1756-7874

Section: Research & Development



Laying the foundation to its immuno-oncology business, Coherus BioSciences has partnered with Shanghai Junshi Biosciences for the development and commercialisation of Junshi’s anti-PD-1 antibody, toripalimab, in the US and Canada...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details